Search Results

Scinai Immunotherapeutics Ltd. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,606,552 American Depositary Shares, each representing four hundred ordinary shares, having exercise prices ranging from $1.16 to $5.00 per ADS and terms ranging from five and one-half years to three years, respectively, issued by Scinai in September 2023 and December 2022, at a reduced exercise price of $0.65 per ADS.

Scinai Immunotherapeutics Ltd. announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 2,606,552 American Depositary Shares, each representing four hundred ordinary shares, having exercise prices ranging from $1.16 to $5.00 per ADS and terms ranging from five and one-half years to three years, respectively, issued by Scinai in September 2023 and December 2022, at a reduced exercise price of $0.65 per ADS.

According to Nova one advisor, the global Bioinformatics market size is expected to hit around USD 45.9 billion by 2030 from valued at USD 24.7 billion in 2021 and growing at a CAGR of 16.9% from 2022 to 2030.

Emtora Biosciences announced it has been awarded a $16.9M non-dilutive grant from the Cancer Prevention & Research Institute of Texas to advance the clinical and product development of its lead program, eRapaTM, an encapsulated form of rapamycin, for the treatment of Familial Adenomatous Polyposis.

According to Emergen Research, the global mobile C-arms market size was USD 1.12 billion in 2020 and is expected to reach USD 1.69 billion in 2028 and register a revenue CAGR of 5.2% during the forecast period, 2021-2028.

According to Emergen Research, the global robotics surgical simulation systems market size was USD 476.8 Million in 2020 and is expected to reach USD 1.69 Billion in 2028 and register a revenue CAGR of 17.0% during the forecast period, 2021-2028.

Apogee Therapeutics, LLC, a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders, today announced the closing of a $149 million Series B financing.